Anika Therapeutics (ANIK +3%) says that it expects FY12 and Q4 to come in better than...

|About: Anika Therapeutics Inc. (ANIK)|By:, SA News Editor

Anika Therapeutics (ANIK +3%) says that it expects FY12 and Q4 to come in better than expections. Q4 revenue should come in around $22M - $23M, above the current consensus estimate of $20.6M. For FY12, it expects to equal or exceed its previously announced guidance of $0.74 net income per diluted share. Additionally it's appointed Sylvia Cheung as its new CFO, effective April 1, 2013. Cheung will replace Kevin Quinlan, who is leaving effective March 31, 2013.